AppLovin Stock: Is It Time to Buy the Dip?

AppLovin Stock: Is It Time to Buy the Dip?

AppLovin stock posted 59% revenue growth and a 70% free cash flow margin in Q1 2026—numbers that look more like cheat codes than a real business. We break down what makes the Axon 2.0 machine learning ad engine so efficient, why AppLovin can scale without a traditional sales force, and how targeted digital advertising has become the clearest ROI story in AI so far.


We also walk through management's 10-year growth roadmap—from mobile gaming to consumer, e-commerce, and connected TV—and what has to be true for AppLovin to reach $70 billion in annual revenue. Then we run both a five-year and ten-year reverse DCF to show exactly what growth rate is already baked into the current stock price, and whether buying the dip today makes sense for long-term investors. Plus, how they're deploying $1.3 billion in quarterly free cash flow, including nearly $1 billion in share buybacks in Q1 alone.


Want real-time portfolio access and deeper coverage on high-growth software and semiconductor stocks? Join Semi Insider at chipstockinvestor.com.

Run your own AppLovin research with AI-powered financial tools at fiscal.ai/csi — 15% off any paid plan.

Content in this video is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal.CSI owns shares of AppLovin.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(492)

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience (TWST) just had a massive run-up after Anthropic's protein design results put its DNA synthesis platform in the spotlight. Here's what's really driving the stock — and whether it's st...

17 Sep 14min

The Fastest-Growing Chip Stock Is Also the Most Hated

The Fastest-Growing Chip Stock Is Also the Most Hated

We compare Credo (CRDO) against Broadcom (AVGO), Marvell (MRVL), and Astera Labs (ALAB) on revenue growth, gross margin, operating margin, and free cash flow margin — four fabless companies selling in...

15 Sep 13min

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

We break down the takeaways from Oracle's (ORCL) Q1 fiscal 2027 earnings call — what to expect through 2026 and into 2027–2028 as hyperscaler CapEx stays high but is set to slow in growth by 2027, and...

14 Sep 12min

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia just proposed its largest acquisition ever — $12.9 billion for Hugging Face. But regulators in the US, EU, and China may have other plans.Nvidia has announced plans to acquire Hugging Face, the...

10 Sep 15min

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage just rebranded to Everpure — and in the same stretch, free cash flow went negative 20% in a single quarter. Here's what's really going on.Pure Storage has officially rebranded as Everpure...

10 Sep 19min

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept BioRobotics is down roughly 80% from its 2025 highs but the technology behind its Aquablation system genuinely works. So why won't we put PRCT in our portfolio?Procept (PRCT) has one of the mo...

10 Sep 28min

Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Oscar Health looks like a screaming buy — growing revenue, growing members, positive free cash flow. So why does the market keep discounting it? We ran the numbers.Oscar Health (OSCR) just posted stro...

10 Sep 11min

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Networks (PANW) has been flying high into the end of FY2026. After a decade-long 1,400% run — capped by a broader cybersecurity rally following the Anthropic "Mythos moment" in early 2026 — ...

2 Sep 14min

Populärt inom Business & ekonomi

framgangspodden
varvet
rss-jossan-nina
rss-borsens-finest
svd-tech-brief
24fragor
avanzapodden
badfluence
uppgang-och-fall
rss-inga-dumma-fragor-om-pengar
lastbilspodden
fill-or-kill
rss-dagen-med-di
rss-kort-lang-analyspodden-fran-di
rikatillsammans-om-privatekonomi-rikedom-i-livet
tabberaset
bathina-en-podcast
kapitalet-en-podd-om-ekonomi
borsmorgon
affarsvarlden